Loading...
Loading...
ITCI| Name | Value |
|---|---|
| Revenues | 125.8M |
| Cost of Revenue | 9.1M |
| Gross Profit | 116.7M |
| Operating Expense | 146.4M |
| Operating I/L | -29.7M |
| Other Income/Expense | 5.5M |
| Interest Income | 5.5M |
| Pretax | -24.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -24.3M |
Intra-Cellular Therapies, Inc. is a biopharmaceutical company specializing in the development of novel drugs targeting intracellular signaling mechanisms within the central nervous system. The company's flagship product, CAPLYTA, is designed for the treatment of schizophrenia in adults. In addition, it is actively involved in the development of lumateperone for bipolar depression and autism spectrum disorder, as well as other neuropsychiatric indications. Furthermore, the company is working on Lenrispodun for Parkinson's disease and heart failure, ITI-1284-ODT-SL for neuropsychiatric disorders and behavioral disturbances in dementia, and ITI-333 for substance use disorders, pain, and psychiatric comorbidities.
